DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week's acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics.
"As European nations scale their screening ambitions and confront rising workload pressures, our integrated portfolio is designed to stage shift disease, empower diagnostic excellence and expand patient access, thereby driving precision care," said Niccolo Stefani, MD, Business Leader Population Health & Clinical AI, DeepHealth. "These solutions transform imaging pathways, enabling healthcare systems to move from reactive treatment to proactive intervention while addressing the realities of diverse European markets, to improve patient outcomes."
The Industry's MostComprehensiveNativeClinicalAI Portfolio
DeepHealth's expanded European portfolio now delivers a fully integrated, end-to-end suite of modular AI solutions, validated by clinical evidence and proof at scale in real-world settings. Designed to stage-shift disease through earlier detection, the portfolio enhances diagnostic consistency while driving meaningful gains in operational efficiency.
- Breast Suite.i A modular solution that integrates AI-powered detection, risk assessment,ii breast density analysis and new mammography analytics based on our recent acquisition of Aquila. Aquila's solution complements DeepHealth's existing AI-powered breast imaging portfolio by adding the ability to measure, monitor and improve image quality across technologists, sites and workflows, thereby strengthening clinical teams and enabling connected, scalable care in high-volume screening environments with the strict compliance standards. A landmark Nature Health study validated the real-world impact of applications within the Suite, demonstrating a 21% increase in breast cancer detection rate among over 579,000 women.iii For the millions of women with dense breasts or elevated breast cancer risk, supplemental ultrasound is a critical complement to mammography — and DeepHealth is now extending its Breast Suite to include AI-powered breast ultrasound, building on the strategic acquisition and integration of See-Mode. Moving from detection to proactive care, Breast Suite's AI-powered risk assessment tool predicts a patient's near-term risk of developing cancer based only on a mammogram, with 2x greater accuracy than traditional risk models.ivv At ECR 2026, DeepHealth will present researchvi showing its AI breast arterial calcifications (BAC)vii algorithm accurately detects cardiovascular risk indicators directly from routine mammography — extending the Breast Suite's clinical value beyond cancer detection.
- Chest Suite: Chest Suiteviii applications automate pulmonary nodule detection, characterization and volumetric quantification with standardized reporting and longitudinal tracking — with the ultimate goal of stage-shifting lung cancer. Applications of this suite support the NHS England's Lung Cancer Screening program and France's CASCADE lung cancer screening study, validating AI's role in population-based lung-cancer screening. DeepHealth will present research at ECR 2026ixx confirming that AI-assisted nodule detection significantly improves radiologists' diagnostic accuracy, interobserver agreement and read efficiency — with consistent performance across both routine clinical and screening low-dose CT examinations.
- Neuro Suite: Neuro Suitexi applications automate neuroimaging analysis to enable proactive neurological care, automatically quantifying key brain structures, including the hippocampus, cortical lobes and subcortical regions, to support precise longitudinal tracking and early intervention for neurodegenerative conditions. Awarded "Best AI in Healthcare 2023" at the Italian Health System Forum, applications within Neuro Suite demonstrated 92% sensitivity in the early identification of hippocampal atrophy associated with mild cognitive disorders and Alzheimer's disease.xii Central to the solution is its white matter hyperintensity (WMH) algorithm, with DeepHealth research presented at ECR 2026xiii demonstrating expert-level automated quantification and consistent anatomical labeling across multiple FLAIR MRI scans — delivering the granular, reproducible biomarker data that enables meaningful risk stratification and longitudinal assessment at scale.
- Prostate Suite: Prostate Suitexiv integrates automated lesion detection and risk classification, intelligent gland segmentation with PSA density calculation and PI-RADS-compliant reporting into one seamless platform, supporting more than nine fusion biopsy systems to eliminate manual data transfer and support radiologists at every critical decision point. Prostate Suite application has been chosen to support TRANSFORM, the U.K.'s largest prostate cancer screening trial in a generation. At ECR, DeepHealth will present a multi-reader study,xv which found applications of the Suite improved radiologists' area under the curve (AUC) and more than doubled interobserver agreement.
- Thyroid Suite: Thyroid Suitexvi is an AI-powered, modular solution that automates nodule detection, characterization, measurements and reporting within existing thyroid ultrasound workflows, building on the acquisition and integration of See-Mode. Deployment across more than 200 RadNet sites has demonstrated transformative real-world impact: radiologists accepted AI-based measurements and characterization without correction in greater than 94% of casesxvii and the ability to reduce scan slot time by up to 30%,xviii thereby expanding clinical capacity. DeepHealth's ECR 2026 clinical dataxix reinforces this impact, showing that AI assistance significantly reduced interpretation time while improving radiologist accuracy, agreement and consistency in thyroid nodule characterization.
- AIStudio:Supporting its integrated Population Health suites, DeepHealth's AI Studio Suite provides a unified platform to accelerate enterprise-wide AI adoption with confidence. AI Studio adds more than 140 AI algorithms from over 75 ecosystem partners — alongside DeepHealth's own clinical AI applications — and seamlessly orchestrates them within the clinical workflow, including the worklist, viewer, reporting modules and workflow engine. The platform enhances automation, streamlines deployment and elevates the viewing and reporting experience. In parallel, AI Studio delivers comprehensive governance capabilities, including AI validation, continuous monitoring and drift management in production, ensuring consistent performance and the safe, reliable scaling of AI across the healthcare enterprise.
"DeepHealth's unified platform has fundamentally changed how we serve our patients," commented the medical leadership of Emicenter Diagnostic Center in Italy. "From prostate and lung cancer screening to the assessment of neurodegenerative disease, we now have one cohesive, AI-powered ecosystem that gives our radiologists the clinical confidence to detect disease earlier and the workflow efficiency to do it at scale."